Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy HUL, Dabur, Cipla, Glenmark: CK Narayan

      According to CK Narayan, MD at Growth Avenues, one can buy Hindustan Unilever, Dabur India, Cipla and Glenmark Pharma.

    • Buy Glenmark Pharma, says Gaurav Bissa

      Gaurav Bissa, Derivatives Analyst at LKP Securities recommends buying Glenmark Pharma as the stock may head above Rs 895.

    • Buy Glenmark Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma as the stock may head higher.

    • Hitesh Mahida cautious on Lupin, prefers Dr Reddy's Labs

      Hitesh Mahida of Antique Stock Broking is cautious on Lupin and feels that one can buy Dr Reddy‘s Laboratories and Glenmark Pharma.

    • Hitesh Mahida positive on Glenmark Pharma

      Hitesh Mahida of Antique Stock Broking has a positive view on Glenmark Pharma.

    • Enter Glenmark Pharma at around Rs 755: Rahul Mohinder

      Rahul Mohindar of viratechindia.com is of the view that one may enter Glenmark Pharma at around Rs 755.

    • Glenmark Pharma may touch Rs 820, says Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that Glenmark Pharma may test Rs 820.

    • Prefer ICICI Bank, Axis Bank: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer ICICI Bank and Axis Bank.

    • Go long in Glenmark Pharma: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group recommends going long in Glenmark Pharma with a target of Rs 810-815 in next three-four trading sessions.

    • Buy Glenmark Pharma on dips: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Glenmark Pharma.

    • Buy Glenmark Pharma 740 Call, says VK Sharma

      VK Sharma of HDFC Securities recommends buying Glenmark Pharma 740 Call.

    • Accumulate Dr Reddy's Labs on every dip, says Deven Choksey

      Deven Choksey of KR Choksey Shares & Securities recommends accumulating Dr Reddy's Laboratories on every dip and feels that Glenmark Pharma and Cipla holds good potential for an upmove going forward.

    • Buy Glenmark Pharma, advises Pritesh Mehta

      Pritesh Mehta - Senior Technical Analyst at IIF recommends buying Glenmark Pharma with a target of Rs 780.

    • Prefer Glenmark, Lupin: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may prefer Lupin, Cipla or a Glenmark from pharma space.

    • Prefer pharma space, says Dilip Bhat

      According to Dilip Bhat of Prabhudas Lilladher, one may bet on pharmaceutical space.

    • Here are top 10 stocks to keep an eye on December 29

      Here are top 10 stocks to keep an eye on December 29 - United Bank, Spice Mobility, SBI, ICICI Bank, Spicejet, JSL Stainless, Jindal Photo, Jindal Poly, Career Point and Glenmark Pharma.

    • Here are top 10 stocks to focus on December 15

      Here are top 10 stocks to focus on December 15 – Mahindra and Mahindra (M&M), HCL Technologies, India Cement, Gas Authority of India (GAIL), Tata Consultancy Services (TCS), Bank Nifty, Dr Reddy's, Glenmark, Havells and SpiceJet.

    • Buy Glenmark Pharma: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can buy Glenmark Pharma on dips.

    • Glenmark Pharma may go upto Rs 900-950: Amit Gupta

      Amit Gupta of ICICI Direct feels that Glenmark Pharma may go upto Rs 900-950.

    • Buy Glenmark Pharma, says Yogesh Mehta

      Yogesh Mehta, Associate VP- PCG Advisory - Equities at Motilal Oswal is of the view that one can buy Glenmark Pharma as the stock may test Rs 860-870.

    • Super Six: Top chart picks for November 21

      Vishal Kshatriya of Edelweiss recommends buying Hexaware Technologies for a target price of Rs 235-240 and Cipla with a target of Rs 640.

    • Buy Glenmark, HUL, Shriram Transport: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma, Hindustan Unilever and Shriram Transport Finance Corporation.

    • Buy Glenmark Pharma, positive on Crompton: Amit Gupta

      Amit Gupta of ICICIdirect recommends buying Glenmark Pharma as the stock may test Rs 870 and has a positive view on Crompton Greaves.

    • Is Sun Pharma expensive at current valuations?

      Purely from a short-term point of view there might not be too much of significant run up but purely on a fundamental basis Sun Pharma looks fairly strong, does warrant a presence in portfolios, has a fair amount of institutional investment as well, says Nipun Mehta.

    • Buy Glenmark Pharma, says Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Glenmark Pharma with a target of Rs 780.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347